Current and future treatment strategies in chronic lymphocytic leukemia
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Current and future treatment strategies in chronic lymphocytic leukemia
Authors
Keywords
-
Journal
Journal of Hematology & Oncology
Volume 14, Issue 1, Pages -
Publisher
Springer Science and Business Media LLC
Online
2021-04-26
DOI
10.1186/s13045-021-01054-w
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Results from a First-in-Human, Proof-of-Concept Phase 1 Trial in Pretreated B-Cell Malignancies for Loxo-305, a Next-Generation, Highly Selective, Non-Covalent BTK Inhibitor
- (2020) Anthony R. Mato et al. BLOOD
- Ibrutinib, Fludarabine, Cyclophosphamide, and Obinutuzumab (iFCG) for First-Line Treatment of IGHV-Mutated CLL and without Del(17p)/Mutated TP53
- (2020) Nitin Jain et al. BLOOD
- Efficacy and Safety of Duvelisib Following Disease Progression on Ofatumumab in Patients with Relapsed/Refractory CLL or SLL in the DUO Crossover Extension Study
- (2020) Matthew S. Davids et al. CLINICAL CANCER RESEARCH
- Novel targeted therapies for Chronic Lymphocytic Leukemia in elderly patients. A systematic review
- (2020) Arafat Ali Farooqui et al. Clinical Lymphoma Myeloma & Leukemia
- Zanubrutinib: First Approval
- (2020) Yahiya Y. Syed DRUGS
- Experiences of living with chronic myeloid leukaemia and adhering to tyrosine kinase inhibitors: A thematic synthesis of qualitative studies
- (2020) Ann Hewison et al. European Journal of Oncology Nursing
- Preclinical efficacy for a novel tyrosine kinase inhibitor, ArQule 531 against acute myeloid leukemia
- (2020) Ola A. Elgamal et al. Journal of Hematology & Oncology
- Use of CAR-Transduced Natural Killer Cells in CD19-Positive Lymphoid Tumors
- (2020) Enli Liu et al. NEW ENGLAND JOURNAL OF MEDICINE
- Revolution of Chronic Lymphocytic Leukemia Therapy: the Chemo-Free Treatment Paradigm
- (2020) Annika Scheffold et al. Current Oncology Reports
- Acalabrutinib plus Obinutuzumab in Treatment-Naïve and Relapsed/Refractory Chronic Lymphocytic Leukemia
- (2020) Jennifer A. Woyach et al. Cancer Discovery
- BTK inhibitor therapy is effective in patients with CLL resistant to venetoclax
- (2020) Victor S Lin et al. BLOOD
- Novel Therapies in Chronic Lymphocytic Leukemia: A Rapidly Changing Landscape
- (2020) Lorenzo Iovino et al. CURRENT TREATMENT OPTIONS IN ONCOLOGY
- ALPINE: zanubrutinib versus ibrutinib in relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma
- (2020) Peter Hillmen et al. Future Oncology
- Tolerability and durable respones of the PI3Kδ inhibitor ME-401 administered on an intermittent schedule in relapsed/refractory (R/R) follicular lymphoma (FL) and other B-cell malignancies.
- (2020) Andrew David Zelenetz et al. JOURNAL OF CLINICAL ONCOLOGY
- ASPEN: Results of a phase III randomized trial of zanubrutinib versus ibrutinib for patients with Waldenström macroglobulinemia (WM).
- (2020) Constantine Si Lun Tam et al. JOURNAL OF CLINICAL ONCOLOGY
- Fixed-duration venetoclax-obinutuzumab for previously untreated patients with chronic lymphocytic leukemia: Follow-up of efficacy and safety results from the multicenter, open-label, randomized, phase III CLL14 trial.
- (2020) Othman Al-Sawaf et al. JOURNAL OF CLINICAL ONCOLOGY
- Acalabrutinib with or without obinutuzumab versus chlorambucil and obinutuzumab for treatment-naive chronic lymphocytic leukaemia (ELEVATE-TN): a randomised, controlled, phase 3 trial
- (2020) Jeff P Sharman et al. LANCET
- The impact of dose modification and temporary interruption of ibrutinib on outcomes of chronic lymphocytic leukemia patients in routine clinical practice
- (2020) Sameer A. Parikh et al. Cancer Medicine
- Bispecific, T-Cell-Recruiting Antibodies in B-Cell Malignancies
- (2020) Margaux Lejeune et al. Frontiers in Immunology
- Ibrutinib dose modifications in the management of CLL
- (2020) Camille Hardy-Abeloos et al. Journal of Hematology & Oncology
- Phase II Study of Combination Obinutuzumab, Ibrutinib, and Venetoclax in Treatment-Naïve and Relapsed or Refractory Chronic Lymphocytic Leukemia
- (2020) Kerry A. Rogers et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase 2 Study of the Safety and Efficacy of Umbralisib in Patients with CLL Who Are Intolerant to BTK or PI3Kδ Inhibitor Therapy
- (2020) Anthony R. Mato et al. BLOOD
- Impact of dosing frequency (once daily or twice daily) on patient adherence to oral targeted therapies for hematologic malignancies: a retrospective cohort study among managed care enrollees
- (2019) Krish Patel et al. JOURNAL OF ONCOLOGY PHARMACY PRACTICE
- Tolerability and activity of ublituximab, umbralisib, and ibrutinib in patients with chronic lymphocytic leukaemia and non-Hodgkin lymphoma: a phase 1 dose escalation and expansion trial
- (2019) Loretta J Nastoupil et al. Lancet Haematology
- Outcomes with ibrutinib by line of therapy and post-ibrutinib discontinuation in patients with chronic lymphocytic leukemia: Phase 3 analysis
- (2019) Susan M. O'Brien et al. AMERICAN JOURNAL OF HEMATOLOGY
- Ibrutinib and Venetoclax for First-Line Treatment of CLL
- (2019) Nitin Jain et al. NEW ENGLAND JOURNAL OF MEDICINE
- A review of bispecific antibodies and antibody constructs in oncology and clinical challenges
- (2019) Frans V. Suurs et al. PHARMACOLOGY & THERAPEUTICS
- Treatment patterns, adverse events, and economic burden in a privately insured population of patients with chronic lymphocytic leukemia in the United States
- (2019) Shaum M. Kabadi et al. Cancer Medicine
- Chronic lymphocytic leukemia: 2019 update on diagnosis, risk stratification and treatment
- (2019) Michael Hallek AMERICAN JOURNAL OF HEMATOLOGY
- Phase 1 study of selective BTK inhibitor zanubrutinib in B-cell malignancies and safety and efficacy evaluation in CLL
- (2019) Constantine Si Lun Tam et al. BLOOD
- PHASE I CLINICAL TRIAL OF CD19-TARGETED 19-28Z/4-1BBL “ARMORED” CAR T CELLS IN PATIENTS WITH RELAPSED OR REFRACTORY NHL AND CLL INCLUDING RICHTER TRANSFORMATION
- (2019) C.L. Batlevi et al. HEMATOLOGICAL ONCOLOGY
- IBRUTINIB VERSUS PLACEBO IN PATIENTS WITH ASYMPTOMATIC, TREATMENT-NAÏVE EARLY STAGE CLL: PRIMARY ENDPOINT RESULTS OF THE PHASE 3 DOUBLE-BLIND RANDOMIZED CLL12 TRIAL
- (2019) P. Langerbeins et al. HEMATOLOGICAL ONCOLOGY
- Acalabrutinib vs Rituximab Plus Idelalisib (IdR) or Bendamustine (BR) by Investigator Choice in Relapsed/Refractory (RR) Chronic Lymphocytic Leukemia: Phase 3 ASCEND Study
- (2019) P. Ghia et al. HEMATOLOGICAL ONCOLOGY
- PHASE 2 STUDY OF ACALABRUTINIB IN IBRUTINIB-INTOLERANT PATIENTS WITH RELAPSED/REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA
- (2019) K.A. Rogers et al. HEMATOLOGICAL ONCOLOGY
- Final Results of a Randomized, Phase III Study of Rituximab With or Without Idelalisib Followed by Open-Label Idelalisib in Patients With Relapsed Chronic Lymphocytic Leukemia
- (2019) Jeff P. Sharman et al. JOURNAL OF CLINICAL ONCOLOGY
- Ibrutinib Plus Venetoclax in Relapsed/Refractory Chronic Lymphocytic Leukemia: The CLARITY Study
- (2019) Peter Hillmen et al. JOURNAL OF CLINICAL ONCOLOGY
- Ibrutinib–Rituximab or Chemoimmunotherapy for Chronic Lymphocytic Leukemia
- (2019) Tait D. Shanafelt et al. NEW ENGLAND JOURNAL OF MEDICINE
- Venetoclax and Obinutuzumab in Patients with CLL and Coexisting Conditions
- (2019) Kirsten Fischer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Exploring a Future for PI3K Inhibitors in Chronic Lymphocytic Leukemia
- (2019) Krish Patel et al. Current Hematologic Malignancy Reports
- Duvelisib for CLL/SLL and Follicular Non-Hodgkin Lymphoma
- (2019) Krish Patel et al. BLOOD
- The impacts of zanubrutinib on immune cells in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma
- (2019) Yi‐Xin Zou et al. HEMATOLOGICAL ONCOLOGY
- Absorption, Distribution, and Binding Profile of ME-401, a Potent and Selective Oral Small-Molecule Inhibitor of Phosphatidylinositol 3-Kinase δ (PI3Kδ) in Animal and B-Cell Lymphoma Models
- (2019) Ofir Moreno et al. Targeted Oncology
- Loxo-305, a Highly Selective and Non-Covalent Next Generation BTK Inhibitor, Inhibits Diverse BTK C481 Substitution Mutations
- (2019) Eliana B. Gomez et al. BLOOD
- Final Results of Phase 1, Dose Escalation Study Evaluating ARQ 531 in Patients with Relapsed or Refractory B-Cell Lymphoid Malignancies
- (2019) Jennifer Woyach et al. BLOOD
- Acalabrutinib monotherapy in patients with relapsed/refractory chronic lymphocytic leukemia: updated phase 2 results
- (2019) John C. Byrd et al. BLOOD
- A CD19/CD3 bispecific antibody for effective immunotherapy of chronic lymphocytic leukemia in the ibrutinib era
- (2018) Hannah R. Robinson et al. BLOOD
- iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL
- (2018) Michael Hallek et al. BLOOD
- A head-to-head Phase III study comparing zanubrutinib versus ibrutinib in patients with Waldenström macroglobulinemia
- (2018) Constantine S Tam et al. Future Oncology
- Real world outcomes and management strategies for venetoclax-treated chronic lymphocytic leukemia patients in the United States
- (2018) Anthony R. Mato et al. HAEMATOLOGICA
- Toxicities and outcomes of 616 ibrutinib-treated patients in the United States: a real-world analysis
- (2018) Anthony R. Mato et al. HAEMATOLOGICA
- Venetoclax for Patients With Chronic Lymphocytic Leukemia With 17p Deletion: Results From the Full Population of a Phase II Pivotal Trial
- (2018) Stephan Stilgenbauer et al. JOURNAL OF CLINICAL ONCOLOGY
- Venetoclax for chronic lymphocytic leukaemia progressing after ibrutinib: an interim analysis of a multicentre, open-label, phase 2 trial
- (2018) Jeffrey A Jones et al. LANCET ONCOLOGY
- Real world outcomes and management strategies for venetoclax-treated chronic lymphocytic leukemia patients in the United States
- (2018) Anthony R. Mato et al. HAEMATOLOGICA
- Toxicities and outcomes of 616 ibrutinib-treated patients in the United States: a real-world analysis
- (2018) Anthony R. Mato et al. HAEMATOLOGICA
- Initial results of a dose escalation study of a selective and structurally differentiated PI3Kδ inhibitor, ME-401, in relapsed/refractory (R/R) follicular lymphoma (FL) and chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL).
- (2018) Jacob Drobnyk Soumerai et al. JOURNAL OF CLINICAL ONCOLOGY
- Bendamustine followed by obinutuzumab and venetoclax in chronic lymphocytic leukaemia (CLL2-BAG): primary endpoint analysis of a multicentre, open-label, phase 2 trial
- (2018) Paula Cramer et al. LANCET ONCOLOGY
- The BTK Inhibitor ARQ 531 Targets Ibrutinib-Resistant CLL and Richter Transformation
- (2018) Sean D. Reiff et al. Cancer Discovery
- The phase 3 DUO trial: duvelisib vs ofatumumab in relapsed and refractory CLL/SLL
- (2018) Ian W. Flinn et al. BLOOD
- Recent advances in CAR T-cell toxicity: Mechanisms, manifestations and management
- (2018) Jennifer N. Brudno et al. BLOOD REVIEWS
- Chimeric antigen receptor-modified T cell therapy in chronic lymphocytic leukemia
- (2018) Yixin Zou et al. Journal of Hematology & Oncology
- Ibrutinib plus obinutuzumab versus chlorambucil plus obinutuzumab in first-line treatment of chronic lymphocytic leukaemia (iLLUMINATE): a multicentre, randomised, open-label, phase 3 trial
- (2018) Carol Moreno et al. LANCET ONCOLOGY
- Ibrutinib Regimens versus Chemoimmunotherapy in Older Patients with Untreated CLL
- (2018) Jennifer A. Woyach et al. NEW ENGLAND JOURNAL OF MEDICINE
- Umbralisib in combination with ibrutinib in patients with relapsed or refractory chronic lymphocytic leukaemia or mantle cell lymphoma: a multicentre phase 1–1b study
- (2018) Matthew S Davids et al. Lancet Haematology
- Durable Molecular Remissions in Chronic Lymphocytic Leukemia Treated With CD19-Specific Chimeric Antigen Receptor–Modified T Cells After Failure of Ibrutinib
- (2017) Cameron J. Turtle et al. JOURNAL OF CLINICAL ONCOLOGY
- BTKC481S-Mediated Resistance to Ibrutinib in Chronic Lymphocytic Leukemia
- (2017) Jennifer A. Woyach et al. JOURNAL OF CLINICAL ONCOLOGY
- Idelalisib or placebo in combination with bendamustine and rituximab in patients with relapsed or refractory chronic lymphocytic leukaemia: interim results from a phase 3, randomised, double-blind, placebo-controlled trial
- (2017) Andrew D Zelenetz et al. LANCET ONCOLOGY
- Assessment of ibrutinib plus rituximab in front-line CLL (FLAIR trial): study protocol for a phase III randomised controlled trial
- (2017) Laura Collett et al. Trials
- Efficacy and safety of idelalisib in combination with ofatumumab for previously treated chronic lymphocytic leukaemia: an open-label, randomised phase 3 trial
- (2017) Jeffrey A Jones et al. Lancet Haematology
- Idelalisib given front-line for treatment of chronic lymphocytic leukemia causes frequent immune-mediated hepatotoxicity
- (2016) B. L. Lampson et al. BLOOD
- An international prognostic index for patients with chronic lymphocytic leukaemia (CLL-IPI): a meta-analysis of individual patient data
- (2016) LANCET ONCOLOGY
- Venetoclax in relapsed or refractory chronic lymphocytic leukaemia with 17p deletion: a multicentre, open-label, phase 2 study
- (2016) Stephan Stilgenbauer et al. LANCET ONCOLOGY
- Acalabrutinib (ACP-196) in Relapsed Chronic Lymphocytic Leukemia
- (2016) John C. Byrd et al. NEW ENGLAND JOURNAL OF MEDICINE
- Economic Burden and Quality-of-Life Effects of Chronic Lymphocytic Leukemia: A Systematic Review of the Literature
- (2016) Simon Frey et al. PHARMACOECONOMICS
- An update on current and prospective immunotherapies for chronic lymphocytic leukemia
- (2015) Josephine N Emole et al. Immunotherapy
- Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia
- (2015) Jan A. Burger et al. NEW ENGLAND JOURNAL OF MEDICINE
- Chimeric antigen receptor T cells persist and induce sustained remissions in relapsed refractory chronic lymphocytic leukemia
- (2015) David L. Porter et al. Science Translational Medicine
- Eradication of bone marrow minimal residual disease may prompt early treatment discontinuation in CLL
- (2014) P. Strati et al. BLOOD
- Resistance Mechanisms for the Bruton's Tyrosine Kinase Inhibitor Ibrutinib
- (2014) Jennifer A. Woyach et al. NEW ENGLAND JOURNAL OF MEDICINE
- Ibrutinib versus Ofatumumab in Previously Treated Chronic Lymphoid Leukemia
- (2014) John C. Byrd et al. NEW ENGLAND JOURNAL OF MEDICINE
- Idelalisib and Rituximab in Relapsed Chronic Lymphocytic Leukemia
- (2014) Richard R. Furman et al. NEW ENGLAND JOURNAL OF MEDICINE
- Comparative Assessment of Clinically Utilized CD20-Directed Antibodies in Chronic Lymphocytic Leukemia Cells Reveals Divergent NK Cell, Monocyte, and Macrophage Properties
- (2013) S. Rafiq et al. JOURNAL OF IMMUNOLOGY
- Retargeting NK-92 cells by means of CD19- and CD20-specific chimeric antigen receptors compares favorably with antibody-dependent cellular cytotoxicity
- (2013) Laurent Boissel et al. OncoImmunology
- B-cell receptor signaling in chronic lymphocytic leukemia
- (2011) F. K. Stevenson et al. BLOOD
- Mechanism of Action of Type II, Glycoengineered, Anti-CD20 Monoclonal Antibody GA101 in B-Chronic Lymphocytic Leukemia Whole Blood Assays in Comparison with Rituximab and Alemtuzumab
- (2011) L. Bologna et al. JOURNAL OF IMMUNOLOGY
- Disease burden of chronic lymphocytic leukaemia within the European Union
- (2008) Louise Watson et al. EUROPEAN JOURNAL OF HAEMATOLOGY
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now